Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An update from Atea Pharmaceuticals ( (AVIR) ) is now available.
On February 20, 2025, Atea Pharmaceuticals appointed Arthur Kirsch as a Class I director. Mr. Kirsch brings extensive experience from his roles in investment banking and advisory positions in the healthcare and life sciences sectors, which the company believes will enhance its strategic direction. His compensation includes an annual cash retainer and equity awards, reflecting Atea’s commitment to leveraging his expertise for future growth.
More about Atea Pharmaceuticals
Atea Pharmaceuticals operates in the healthcare and life sciences industry, focusing on developing and commercializing antiviral therapies.
YTD Price Performance: -9.65%
Average Trading Volume: 424,661
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $261M
Learn more about AVIR stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue